196 related articles for article (PubMed ID: 17138735)
1. 186Re-HEDP in the treatment of patients with inoperable osteosarcoma.
Syed R; Bomanji J; Nagabhushan N; Kayani I; Groves A; Waddington W; Cassoni A; Ell PJ
J Nucl Med; 2006 Dec; 47(12):1927-35. PubMed ID: 17138735
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
3. Re-186 HEDP conditioning therapy in patients with advanced acute lymphoblastic leukemia before allogeneic bone marrow transplantation.
Döbert N; Martin H; Kranert WT; Menzel C; Klein SA; Mose S; Grünwald F
Clin Nucl Med; 2003 Sep; 28(9):738-42. PubMed ID: 12972995
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
5. Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer.
Leondi AH; Souvatzoglou MA; Rapti AS; Leontopoulou SA; Papadaki EK; Datseris EI; Anagnostopoulou US; Zerva CJ
Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):211-9. PubMed ID: 15499295
[TBL] [Abstract][Full Text] [Related]
6. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy for local control of osteosarcoma.
DeLaney TF; Park L; Goldberg SI; Hug EB; Liebsch NJ; Munzenrider JE; Suit HD
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):492-8. PubMed ID: 15667972
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome after polychemotherapy and intensive local radiation therapy of high-grade osteosarcoma.
Hundsdoerfer P; Albrecht M; Rühl U; Fengler R; Kulozik AE; Henze G
Eur J Cancer; 2009 Sep; 45(14):2447-51. PubMed ID: 19596190
[TBL] [Abstract][Full Text] [Related]
9. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
[TBL] [Abstract][Full Text] [Related]
11. Rhenium-186 hydroxyethylidenediphosphonate (186Re HEDP) for the treatment of hemophilic arthropathy: first results.
Bucerius J; Wallny T; Brackmann HH; Joe AY; Roedel R; Biersack HJ; Palmedo H
Clin J Pain; 2007 Sep; 23(7):612-8. PubMed ID: 17710012
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases.
Pirayesh E; Amoui M; Mirzaee HR; Tabei F; Rakhsha A; Kalantari BA; Shafiei B; Assadi M; Asli IN
J Nucl Med Technol; 2013 Sep; 41(3):192-6. PubMed ID: 23918612
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
[TBL] [Abstract][Full Text] [Related]
14. Rhenium-188(Sn)HEDP for treatment of osseous metastases.
Maxon HR; Schroder LE; Washburn LC; Thomas SR; Samaratunga RC; Biniakiewicz D; Moulton JS; Cummings D; Ehrhardt GJ; Morris V
J Nucl Med; 1998 Apr; 39(4):659-63. PubMed ID: 9544677
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model.
Ogawa K; Mukai T; Asano D; Kawashima H; Kinuya S; Shiba K; Hashimoto K; Mori H; Saji H
J Nucl Med; 2007 Jan; 48(1):122-7. PubMed ID: 17204708
[TBL] [Abstract][Full Text] [Related]
17. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals.
Ogawa K; Mukai T; Arano Y; Ono M; Hanaoka H; Ishino S; Hashimoto K; Nishimura H; Saji H
Bioconjug Chem; 2005; 16(4):751-7. PubMed ID: 16029015
[TBL] [Abstract][Full Text] [Related]
18. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
[TBL] [Abstract][Full Text] [Related]
19. A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186(Sn)-HEDP.
Samaratunga RC; Thomas SR; Hinnefeld JD; Von Kuster LC; Hyams DM; Moulton JS; Sperling MI; Maxon HR
J Nucl Med; 1995 Feb; 36(2):336-50. PubMed ID: 7830140
[TBL] [Abstract][Full Text] [Related]
20. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
